Advertisement
Screener

Imunon, Inc. (IMNN) Realized Investment Gains (Losses)

1.1 / 5 stars · 12/57 Roast Me

Imunon, Inc. Realized Investment Gains (Losses)

Imunon, Inc. (IMNN) reported Realized Investment Gains (Losses) of $58.07 thousand for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-14.

Discontinued › Cash Flow › Other Cash Flow Items

us-gaap:RealizedInvestmentGainsLosses · last filed 2019-11-14

  • Imunon, Inc. realized investment gains (losses) for the quarter ending 2019-09-30 was $58.07K, a 1982.78% increase year-over-year.
  • Imunon, Inc. realized investment gains (losses) for the quarter ending 2019-06-30 was $969.00, a 75.17% decline year-over-year.
  • Imunon, Inc. realized investment gains (losses) for the quarter ending 2019-03-31 was $9.38K, a 111.52% increase year-over-year.
  • Imunon, Inc. realized investment gains (losses) for the quarter ending 2018-09-30 was $2.79K.
  • Imunon, Inc. realized investment gains (losses) for fiscal 2012 was $52.32B, a 62.04% increase from fiscal 2011.
  • Imunon, Inc. realized investment gains (losses) for fiscal 2011 was $32.29B, a 30.05% decline from fiscal 2010.
  • Imunon, Inc. realized investment gains (losses) for fiscal 2010 was $46.16B.
Period endRealized Investment Gains (Losses) 3 monthRealized Investment Gains (Losses) 6 monthRealized Investment Gains (Losses) 9 monthRealized Investment Gains (Losses) 12 month
2019-09-30$58.07K
10-Q · filed 2019-11-14
$59.04K
derived: sum of 2 quarters · filed 2019-11-14
$68.42K
10-Q · filed 2019-11-14
2019-06-30$969.00
10-Q · filed 2019-08-14
$10.35K
10-Q · filed 2019-08-14
2019-03-31$9.38K
10-Q · filed 2019-05-15
2018-09-30$2.79K
10-Q · filed 2019-11-14
$6.69K
derived: sum of 2 quarters · filed 2019-11-14
$11.13K
10-Q · filed 2019-11-14
2018-06-30$3.90K
10-Q · filed 2019-08-14
$8.34K
10-Q · filed 2019-08-14
2018-03-31$4.43K
10-Q · filed 2019-05-15
2014-06-30$23.73K
10-Q · filed 2014-08-07
$30.75K
10-Q · filed 2014-08-07
2014-03-31$7.02K
10-Q · filed 2014-05-08
2013-09-30$144.53K
10-Q · filed 2013-11-12
$211.66K
derived: sum of 2 quarters · filed 2014-08-07
$228.23K
10-Q · filed 2013-11-12
$52.32B
derived: sum of 4 quarters · filed 2014-08-07
2013-06-30$67.13K
10-Q · filed 2014-08-07
$83.69K
10-Q · filed 2014-08-07
$52.32B
derived: sum of 3 quarters · filed 2014-08-07
$52.32B
derived: sum of 4 quarters · filed 2014-08-07
2013-03-31$16.56K
10-Q · filed 2014-05-08
$52.32B
derived: sum of 2 quarters · filed 2014-05-08
$52.32B
derived: sum of 3 quarters · filed 2014-05-08
$52.32B
derived: sum of 4 quarters · filed 2014-05-08
2012-12-31$52.32B
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
$52.32B
derived: sum of 2 quarters · filed 2013-11-12
$52.32B
derived: sum of 3 quarters · filed 2013-11-12
$52.32B
10-K · filed 2013-03-18
2012-09-30-$5.58K
10-Q · filed 2013-11-12
$56.49K
derived: sum of 2 quarters · filed 2013-11-12
$61.83K
10-Q · filed 2013-11-12
2012-06-30$62.08K
10-Q · filed 2013-08-08
$67.41K
10-Q · filed 2013-08-08
2012-03-31$5.33K
10-Q · filed 2013-05-09
2011-12-31$32.29B
10-K · filed 2013-03-18
2010-12-31$46.16B
10-K · filed 2013-03-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
SOLIGENIX, INC. (SNGX)United States$0.008B
EXICURE, INC. (XCUR)United States$0.008B-1.54
Traws Pharma, Inc. (TRAW)United States$0.009B-0.58
Alzamend Neuro, Inc. (ALZN)United States$0.009B
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
FibroBiologics, Inc. (FBLG)United States$0.009B-0.27
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97